Tag: BB-031
Reversible thrombolytic could alleviate US “tribalism” around tPA and help redefine...
Following Basking Biosciences’ recent announcement that the first acute ischaemic stroke patients have received its novel thrombolytic therapy as part of the Phase 2...
Basking Biosciences closes US$55 million financing to further reversible stroke thrombolytic
Basking Biosciences has announced the close of US$55 million in financing, which will be used to accelerate clinical development of its novel thrombolytic therapy...
